Mounjaro®
Starting from £179.99/mo
Start journey Learn moreSpots are not a listed side effect of Mounjaro (tirzepatide) in its UK Summary of Product Characteristics, so the medicine itself is unlikely to be the direct cause. That said, skin changes do happen during weight-loss treatment, and understanding why matters. Mounjaro is a prescription-only medicine that requires clinical assessment before it can be dispensed — a prescriber reviews the full picture, including any skin concerns, before treatment begins. If you are noticing spots since starting tirzepatide, several indirect factors are worth understanding, and this page walks through them in the order most people encounter them.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
The Mounjaro SmPC (the definitive clinical document) records injection-site reactions (redness, bruising, swelling, itching at the site itself) and rare systemic hypersensitivity reactions as the skin-related adverse effects to know about. Generalised spots or acne are not on that list. That does not mean your skin cannot change; it means the tirzepatide molecule itself is not thought to trigger acne directly. If you want to read the full adverse-effects section yourself, the NHS tirzepatide medicine page gives a clear plain-English summary. Knowing what is and is not attributable to the medicine is the sensible starting point — it shapes what you do next.
A separate concern some people raise is hair changes rather than spots. These sit in a different physiological category and are covered in detail on our tirzepatide overview page alongside other body-composition questions people ask most often.
When Mounjaro works, several things shift simultaneously. Appetite falls sharply, food intake drops, gastric emptying slows, and body fat begins to reduce. Each of these can have knock-on effects on skin that are nothing to do with tirzepatide as a chemical.
Caloric restriction and rapid dietary change can temporarily alter sebum production in some people, particularly if carbohydrate intake falls steeply and the gut microbiome is adjusting. Early GI side effects (nausea, loose stools, vomiting) are common in the first weeks of treatment per NHS guidance, and if fluid intake suffers as a result, mild dehydration can impair the skin's barrier and make existing pore blockages more visible. Keeping a glass of water by the kettle each morning as a prompting habit is a small practical step some patients find useful.
Hormonal shifts matter too, particularly for women. Body fat is metabolically active and produces oestrogen; as fat mass reduces, sex hormone levels can change, and hormonal fluctuation is a well-established driver of acne. This mechanism is entirely separate from tirzepatide's pharmacology. Our Mounjaro guide has more on what to expect in the first months of treatment.
Most skin changes that appear during weight-loss treatment are benign and self-limiting. If you are trying to make sense of whether a breakout is connected to your treatment, our page covering Mounjaro spots explains the most common patterns people notice and what typically lies behind them. Keep the injection site clean with an understanding of how GI changes are linked, rotate injection sites as instructed, and report persistent redness or swelling at the site to your prescriber.
The symptoms that need prompt medical attention are different in character: a widespread rash, hives, swelling of the face or throat, difficulty breathing, these are signs of a possible allergic reaction and require immediate care. Separately, the MHRA's January 2026 Drug Safety Update for GLP-1 medicines highlighted severe, persistent stomach pain as the warning sign of acute pancreatitis; while not a skin issue, it illustrates the principle that some symptoms cannot wait for a routine check-in. You can report any suspected adverse reaction via the MHRA Yellow Card scheme.
Our dedicated page on whether Mounjaro can cause spots goes deeper into the dermatological evidence, and our clinical team also discusses skin questions regularly in aftercare.
If spots have appeared or worsened since starting tirzepatide and are bothering you, the right move is a prescriber conversation, not a dose change or stopping treatment unilaterally. Skin can react to many variables at once; a clinician can help work out which one is driving the change and whether any adjustment is warranted. Our prescribers provide 7-day aftercare support for exactly this kind of question, it is included in the price, not an extra. For broader context on what a treatment programme at nume involves, take a look at our weight-loss overview.
Questions about cost are sometimes a barrier to asking for help. A clear summary of what is included in treatment pricing (consultation, prescription, delivery and ongoing clinical support) is on our Mounjaro prices page. There are no hidden fees and no subscription structure; every repeat order is reviewed individually.
Skin concerns rarely point to a serious underlying problem, but they are a legitimate reason to reach out. Speak to our prescribers if anything about your skin changes in a way that worries you.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.